In a sector note on U.S. HealthTech & Distribution, Citi lowered the firm's price target on Phibro Animal Health to $44 from $62 and keeps a Neutral rating on the shares. The firm cited "regulatory headwinds and peer multiple compression" for the lowered price target.
